Evaluate Veterans With MGUS for Cardiovascular Disease

Monoclonal gammopathy of undetermined significance (MGUS) is not considered a hematological condition of concern, yet it is associated with lower overall survival. VA researchers led by Lawrence Liu, MD, of the St. Louis VAMC, explored whether the reduced life expectancy arose from an increased risk of cardiovascular events.

GLP-1 Use Reduces Risk of MGUS Progression in Some Veterans

Glucagon-like peptide 1 (GLP-1) receptor agonists have gained huge popularity as they have demonstrated the ability to substantially reduce both blood-glucose levels and weight. In addition, recent research suggests cardiovascular and renal benefits to their use in certain populations.

Older Age of DLBCL Patients Makes Treatment Challenging

Nearly one-half (49%) of all veterans in the United States are 65 years or older. Most of those older veterans (5.5 million) served during the Vietnam era, while 183,000 were World War II veterans, according to the 2021 American Community Survey (ACS). 

VA Will Assess Leukemias, Multiple Myeloma as Presumptive Service Conditions

VA Will Assess Leukemias, Multiple Myeloma as Presumptive Service Conditions

In what could be the first conditions added to the new PACT Act, the VA is conducting a scientific review to determine any relationship between three conditions—acute leukemias, chronic leukemias, and multiple myeloma outside of the head and neck—and toxic exposures for servicemembers who deployed to Iraq, Afghanistan, Somalia, Djibouti, Egypt, Jordan, Lebanon, Syria, Yemen, Uzbekistan, and the entire Southwest Asia theater of operations.